SobreNegócios
AjudaPrivacidadeCondições
ResumoLegal e statusLinha do tempoRedePropriedade e gestãoAcionistasBeneficiário efetivoGeografiaFinançasSaúde financeiraDocumentos
ResumoLegal e statusLinha do tempoRedePropriedade e gestãoAcionistasBeneficiário efetivoGeografiaFinançasSaúde financeiraDocumentos

BIOSCRIPT MIDCO 2 LIMITED

🇬🇧Reino Unido•Private Limited Company (Ltd.)•Ativa

Resumo

País🇬🇧Reino Unido
EstadoAtiva
Número de registro13212966
Fundada19/02/2021
Objeto socialActivities of other holding companies n.e.c.
EndereçoSuite A, Greenway House Larkwood Way, Tytherington Business Park, Macclesfield, SK10 2XR
Declaração de confirmaçãoPróximo vencimento: 06/02/2027; Última elaboração: —

Legal e status

Forma legalPrivate Limited Company (Ltd.)
EstadoAtiva
Data de registro19/02/2021
Autoridade registralCompanies House
Capital registrado—

Fonte: UK Companies House · Última atualização: 03/12/2025

Linha do tempo (24 eventos)

02/04/2026

Endereço atualizado

Suite A, Greenway House Larkwood Way, Tytherington Business Park

27/06/2025

Contas anuais apresentadas

Full accounts made up to 30 September 2024

Ver ficheiro em Documentos

19/02/2021

Nomeação Trevor Stokes (pessoa)

Nomeado como Director

Rede

Este diagrama tem muitas conexões. para uma melhor experiência.
Press enter or space to select a node. You can then use the arrow keys to move the node around. Press delete to remove it and escape to cancel.
Press enter or space to select an edge. You can then press delete to remove it or escape to cancel.
Profundidade da rede

Propriedade e gestão

Persons with significant control

Bioscript Midco 1 Limited

75–100% shares · 75–100% voting rights · Right to appoint directors

Nomeado em: 19/02/2021

87.5%
Bioscript Midco 1 Limited

75–100% shares · 75–100% voting rights · Right to appoint directors

Nomeado em: 19/02/2021

87.5%

Officers & directors

James Maxwell

Director

Nomeado em: 15/02/2024

—
Gabrielle Alison Silver

Director

Nomeado em: 02/05/2023

—
Daniel Chaffer

Director

Nomeado em: 07/07/2021 · Demitido em: 14/07/2023

—

Mostrando 1–5 de 8

1 / 2

Linha do tempo de propriedade (2 alterações)

19/02/2021

Nomeação Bioscript Midco 1 Limited (pessoa)

Pessoa com controle significativo

19/02/2021

Nomeação Bioscript Midco 1 Limited (empresa)

owns or controls

Acionistas

NomeParticipaçãoVotoDesde
▓▓▓▓▓▓▓▓▓▓▓▓
█.██%
██%
█.█%
▓▓▓▓▓▓▓▓▓▓▓
██%
█.█%
██.██%
▓▓▓▓▓▓▓▓▓▓▓▓▓
█.█%
██.██%
██.█%
▓▓▓▓▓▓▓▓▓▓
██.██%
██.█%
█.██%
▓▓▓▓▓▓▓▓▓▓▓▓
██.█%
█.██%
██%
▓▓▓▓▓▓▓▓▓▓▓
█.██%
██%
█.█%
▓▓▓▓▓▓▓▓▓▓▓▓▓
██%
█.█%
██.██%
▓▓▓▓▓▓▓▓▓▓
█.█%
██.██%
██.█%

Beneficiário efetivo

NomeParticipaçãoPaísDesde
▓▓▓▓▓▓▓▓▓▓▓▓
█.██%
██%
█.█%
▓▓▓▓▓▓▓▓▓▓▓
██%
█.█%
██.██%
▓▓▓▓▓▓▓▓▓▓▓▓▓
█.█%
██.██%
██.█%
▓▓▓▓▓▓▓▓▓▓
██.██%
██.█%
█.██%
▓▓▓▓▓▓▓▓▓▓▓▓
██.█%
█.██%
██%
▓▓▓▓▓▓▓▓▓▓▓
█.██%
██%
█.█%
▓▓▓▓▓▓▓▓▓▓▓▓▓
██%
█.█%
██.██%
▓▓▓▓▓▓▓▓▓▓
█.█%
██.██%
██.█%

Geografia

Sede

Suite A

Greenway House Larkwood Way, Tytherington Business Park

Macclesfield

SK10 2XR

Finanças

Indicadores das demonstrações anuais.

Converter para

2021

Lucro / (prejuízo): £0

Indicadores

Lucro / (prejuízo)

2021£0
2022£0
2023£0
2024£0

Outras receitas

2021£1.628.440
2022£1.628.440
2023£3.652.957
2024£3.913.386

Ativo total

2021£2.819.297
2022£2.819.297
2023£7.151.967
2024£7.167.326

Net Assets Liabilities

2021£2.819.297
2022£2.819.297
2023£7.151.967
2024£7.167.326

Equity

2021£2.819.297
2022£2.819.297
2023£7.151.967
2024£7.167.326

Current Assets

2021£29.659.379
2022£29.659.379
2023£37.203.541
2024£44.146.534

Net Current Assets Liabilities

2021£-4.761
2022£-4.761
2023£-4.761
2024£-4.761

Total Assets Less Current Liabilities

2021£2.819.297
2022£2.819.297
2023£7.151.967
2024£7.167.326

Debtors

2021£29.659.379
2022£29.659.379
2023£37.203.541
2024£44.146.534

Creditors

2021£29.664.140
2022£29.664.140
2023£37.208.302
2024£44.151.295

Amounts Owed To Group Undertakings

2021£29.659.379
2022£29.659.379
2023£37.208.302
2024£44.151.295

Investments Fixed Assets

2021£2.824.058
2022£2.824.058
2023£7.156.728
2024£7.172.087

Issue Equity Instruments

2021—
2022£2.824.058
2023£4.332.670
2024£900.000

Number Shares Issued Fully Paid

202196.301
202296.301
2023432.342.829
2024432.342.829

Par Value Share

2021£0
2022£0
2023£0
2024£0

Despesas administrativas

2021£4.761
2022£4.761
2023—
2024—

Accrued Liabilities Deferred Income

2021£4.761
2022£4.761
2023—
2024—

Amounts Owed By Group Undertakings

2021£29.659.379
2022£29.659.379
2023£37.203.541
2024£44.146.534

Applicable Tax Rate

2021£0
2022£0
2023—
2024—

Audit Fees Expenses

2021£2.000
2022£2.000
2023—
2024—

Comprehensive Income Expense

2021—
2022£-4.761
2023£0
2024£0

Fixed Assets

2021£2.824.058
2022£2.824.058
2023£7.156.728
2024£7.172.087

Further Item Increase Decrease In Equity Component Total Income Expense Recognised Directly In Equity

2021—
2022—
2023—
2024£15.359

Income Expense Recognised Directly In Equity

2021—
2022£2.824.058
2023£4.332.670
2024£15.359

Interest Income From Group Undertakings

2021£1.628.440
2022£1.628.440
2023£3.652.957
2024£3.913.386

Interest Paid To Group Undertakings

2021£1.628.440
2022£1.628.440
2023£3.652.957
2024£3.913.386

Interest Payable Similar Charges Finance Costs

2021£1.628.440
2022£1.628.440
2023£3.652.957
2024£3.913.386

Operating Profit Loss

2021£-4.761
2022£-4.761
2023—
2024—

Other Interest Receivable Similar Income Finance Income

2021£1.628.440
2022£1.628.440
2023£3.652.957
2024£3.913.386

Percentage Class Share Held In Subsidiary

2021£1
2022£1
2023£1
2024£1

Profit Loss On Ordinary Activities After Tax

2021£-4.761
2022£-4.761
2023£0
2024£0

Profit Loss On Ordinary Activities Before Tax

2021£-4.761
2022£-4.761
2023£0
2024£0

Tax Expense Credit Applicable Tax Rate

2021£-905
2022£-905
2023—
2024—

Tax Increase Decrease Arising From Group Relief Tax Reconciliation

2021£905
2022£905
2023—
2024—
Métrica2021202220232024
Lucro / (prejuízo)£0£0£0£0
Outras receitas£1.628.440£1.628.440£3.652.957£3.913.386
Ativo total£2.819.297£2.819.297£7.151.967£7.167.326
Net Assets Liabilities£2.819.297£2.819.297£7.151.967£7.167.326
Equity£2.819.297£2.819.297£7.151.967£7.167.326
Current Assets£29.659.379£29.659.379£37.203.541£44.146.534
Net Current Assets Liabilities£-4.761£-4.761£-4.761£-4.761
Total Assets Less Current Liabilities£2.819.297£2.819.297£7.151.967£7.167.326
Debtors£29.659.379£29.659.379£37.203.541£44.146.534
Creditors£29.664.140£29.664.140£37.208.302£44.151.295
Amounts Owed To Group Undertakings£29.659.379£29.659.379£37.208.302£44.151.295
Investments Fixed Assets£2.824.058£2.824.058£7.156.728£7.172.087
Issue Equity Instruments—£2.824.058£4.332.670£900.000
Number Shares Issued Fully Paid96.30196.301432.342.829432.342.829
Par Value Share£0£0£0£0
Despesas administrativas£4.761£4.761——
Accrued Liabilities Deferred Income£4.761£4.761——
Amounts Owed By Group Undertakings£29.659.379£29.659.379£37.203.541£44.146.534
Applicable Tax Rate£0£0——
Audit Fees Expenses£2.000£2.000——
Comprehensive Income Expense—£-4.761£0£0
Fixed Assets£2.824.058£2.824.058£7.156.728£7.172.087
Further Item Increase Decrease In Equity Component Total Income Expense Recognised Directly In Equity———£15.359
Income Expense Recognised Directly In Equity—£2.824.058£4.332.670£15.359
Interest Income From Group Undertakings£1.628.440£1.628.440£3.652.957£3.913.386
Interest Paid To Group Undertakings£1.628.440£1.628.440£3.652.957£3.913.386
Interest Payable Similar Charges Finance Costs£1.628.440£1.628.440£3.652.957£3.913.386
Operating Profit Loss£-4.761£-4.761——
Other Interest Receivable Similar Income Finance Income£1.628.440£1.628.440£3.652.957£3.913.386
Percentage Class Share Held In Subsidiary£1£1£1£1
Profit Loss On Ordinary Activities After Tax£-4.761£-4.761£0£0
Profit Loss On Ordinary Activities Before Tax£-4.761£-4.761£0£0
Tax Expense Credit Applicable Tax Rate£-905£-905——
Tax Increase Decrease Arising From Group Relief Tax Reconciliation£905£905——

Documentos

Registration of particulars of charge

01/05/2026

Ver

Confirmation statement

05/02/2026

Ver

IA de documentos

Em breve

Companexia Document AI

Faça perguntas sobre entregas e extratos—a nossa IA lerá os documentos e responderá em contexto.

Full accounts made up to 30 September 2024

27/06/2025

Ver

Change of director details

07/02/2025

Ver

Confirmation statement

06/02/2025

Ver

Change of details for relevant legal entity with significant control

01/10/2024

Ver

Change of director details

01/10/2024

Ver

Change of director details

01/10/2024

Ver

Annual Accounts

Contas do exercício que termina em: 30/09/2024

Arquivado: 30/09/2024

Ver

Mostrando 1–10 de 41

1 / 5

Explorar mais empresas e pessoas

🇮🇪KILDALE LIMITED🇮🇪BRAMBURY LIMITED🇮🇪CLOVERWOOD LIMITEDMichael J. Manzo🇬🇧HULL, Robert JohnNeill Leonard Katz
Rácio de capital próprio (2024)Rácio de capital próprio
100%
Ativos totais ano contra ano (2023 vs. 2024)Ativos totais ano contra ano
+0,2%
CAGR ativos totais (2021–2024)CAGR ativos totais
+36,5%
Ativo circulante líquido (2024)Ativo circulante líquido
-£ 4.761

Saúde financeira

Rácios derivados das contas anuais. Os valores são omitidos quando faltam dados ou não são significativos.

Crescimento

Ativos totais ano contra ano (2022 vs. 2023)
+153,7%
Ativos totais ano contra ano (2023 vs. 2024)
+0,2%
CAGR ativos totais (2021–2024)
+36,5%

Capital circulante e liquidez

Ativo circulante líquido (2021)
-£ 4.761
Ativo circulante líquido (2022)
-£ 4.761
  1. –
  2. –
  3. –BIOSCRIPT MIDCO 2 LIMITED
Ativo circulante líquido (2023)
-£ 4.761
Ativo circulante líquido (2024)
-£ 4.761

Estrutura de capital

Rácio de capital próprio (2021)
100%
Rácio de capital próprio (2022)
100%
Rácio de capital próprio (2023)
100%
Rácio de capital próprio (2024)
100%
Início
Reino Unido
Macclesfield